These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 36974619)

  • 1. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
    Crosbie A; Le TK; Zhang Y; Das R; Ades F; Davis C; Gogate A
    Future Oncol; 2023 Jan; 19(3):229-244. PubMed ID: 36974619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Ilie SM; Briot N; Constantin G; Roussot N; Ilie A; Bergeron A; Arnould L; Beltjens F; Desmoulin I; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Amet A; Coutant C; Coudert B; Bertaut A; Ladoire S
    Breast Cancer; 2023 Nov; 30(6):997-1007. PubMed ID: 37561255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
    Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
    Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
    Wang M; Du S; Gao S; Zhao R; Liu S; Jiang W; Peng C; Chai R; Zhang L
    Breast Cancer Res; 2024 Feb; 26(1):26. PubMed ID: 38347619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Breast and Axillary Pathologic Complete Response in Women Receiving Neoadjuvant Chemotherapy for Breast Cancer.
    Lim DW; Greene BD; Look Hong NJ
    Ann Surg Oncol; 2021 Oct; 28(10):5495-5506. PubMed ID: 34374914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.
    Peterson JR; Cole JA; Pfeiffer JR; Norris GH; Zhang Y; Lopez-Ramos D; Pandey T; Biancalana M; Esslinger HR; Antony AK; Takiar V
    Breast Cancer Res; 2023 May; 25(1):54. PubMed ID: 37165441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Cabrera-Galeana P; Soto-Perez-de-Celis E; Reynoso-Noveron N; Villarreal-Garza C; Lara-Medina F; Alvarado-Miranda A; Espinosa-Fernandez JR; Esparza-Arias N; Mohar A; Bargallo-Rocha JE
    Oncologist; 2020 Dec; 25(12):1023-1031. PubMed ID: 32275801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM; Lowe KA; Atwood M; Beatty JD
    Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.
    Zagami P; Fernandez-Martinez A; Rashid NU; Hoadley KA; Spears PA; Curigliano G; Perou CM; Carey LA
    JAMA Netw Open; 2023 Dec; 6(12):e2348814. PubMed ID: 38117494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
    De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
    Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
    Spring LM; Bar Y; Isakoff SJ
    J Natl Compr Canc Netw; 2022 Jun; 20(6):723-734. PubMed ID: 35714678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
    Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
    J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
    Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
    Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
    Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
    Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.